StemRIM (TSE:4599) Ending Cash Position: 円0.00 Mil (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4599 StemRIM Inc TSE:4599
31 GF Score
Price 円357.00
! 3 Warning Signs
View Full Analysis

What is StemRIM Ending Cash Position?

StemRIM TSE:4599 +1.71% 31 Ending Cash Position is 円0.00 Mil as of Jan. 2026. GuruFocus rates TSE:4599 with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

StemRIM's Ending Cash Position for the quarter that ended in Jan. 2026 was 円0.00 Mil.

StemRIM's annual Ending Cash Position declined from Jul. 2023 (円10,217.76 Mil) to Jul. 2024 (円8,410.45 Mil) and declined from Jul. 2024 (円8,410.45 Mil) to Jul. 2025 (円6,994.59 Mil).

StemRIM Ending Cash Position Related Terms

StemRIM Ending Cash Position Historical Data

* Premium members only.

The historical data trend for StemRIM's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StemRIM Ending Cash Position Chart

StemRIM Annual Data
Trend Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only 10,172.22 8,880.19 10,217.76 8,410.45 6,994.59

StemRIM Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4599
31GF Score
StemRIM Inc TSE:4599
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StemRIM Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

StemRIM's Ending Cash Position for the fiscal year that ended in Jul. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=8410.448+-1415.856
=6,994.59

StemRIM's Ending Cash Position for the quarter that ended in Jan. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0+0
=0.00

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of 円0.00 Mil mean?
StemRIM (TSE:4599) has a Ending Cash Position of 円0.00 Mil as of Jan. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on StemRIM and its competitors.
Is StemRIM's Ending Cash Position too high?
StemRIM's current Ending Cash Position is 円0.00 Mil. Overall, StemRIM has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does StemRIM's Ending Cash Position compare to VRTX and REGN?
StemRIM's Ending Cash Position of 円0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on StemRIM and its competitors. StemRIM's current Ending Cash Position is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemRIM stock overvalued right now?
StemRIM (TSE:4599) has a current Ending Cash Position of 円0.00 Mil. The current Ending Cash Position is 円0.00 Mil. StemRIM's overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For StemRIM (TSE:4599), the current Ending Cash Position is 円0.00 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

StemRIM Business Description

Address 7-15 Ayato Bio Incubator 3rd floor, Ayato Asagi 7-chome, Prefecture Ibaraki City, Osaka, JPN, 567-0085
StemRIM Inc is a biotechnology company engaged in developing regeneration-guided medicines. The business activity of the group includes research, development, manufacture, and sales of pharmaceuticals and medical devices and products such as gene therapy that activate stem cells existing in the body and induce regeneration of damaged tissue.
31GF Score

Get the complete analysis for TSE:4599

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円357.00
Price